文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)的清除仍是未解之谜。

Lipoprotein(a) Removal Still a Mystery.

机构信息

1 Baker Heart & Diabetes Institute Melbourne Australia.

出版信息

J Am Heart Assoc. 2019 Feb 19;8(4):e011903. doi: 10.1161/JAHA.118.011903.

DOI:10.1161/JAHA.118.011903
PMID:30755058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6405664/
Abstract

See Article by Shapiro et al.

摘要

见 Shapiro 等人的文章。

相似文献

[1]
Lipoprotein(a) Removal Still a Mystery.

J Am Heart Assoc. 2019-2-19

[2]
From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.

Eur J Prev Cardiol. 2018-7-30

[3]
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.

J Clin Lipidol. 2017

[4]
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.

Clin Res Cardiol Suppl. 2019-4

[5]
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.

Circulation. 2013-7-24

[6]
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.

Circulation. 2015-10-27

[7]
Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.

Diabetes Obes Metab. 2019-4

[8]
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.

Clin Ther. 2017-10-14

[9]
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.

Nutr Metab Cardiovasc Dis. 2016-10

[10]
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.

Eur Heart J. 2019-9-1

引用本文的文献

[1]
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature.

Biomolecules. 2025-1-22

[2]
Comprehensive Investigation of Circulating Biomarkers and Their Causal Role in Atherosclerosis-Related Risk Factors and Clinical Events.

Circ Genom Precis Med. 2020-12

[3]
Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?

J Clin Med. 2019-11-27

本文引用的文献

[1]
Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.

J Am Heart Assoc. 2019-2-19

[2]
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

Lancet. 2018-10-4

[3]
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.

JAMA Cardiol. 2018-7-1

[4]
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.

Circulation. 2018-9-25

[5]
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.

Circulation. 2018-10-23

[6]
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.

J Clin Lipidol. 2017-10-12

[7]
Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium.

Eur Heart J. 2017-8-21

[8]
Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.

Atherosclerosis. 2017-5

[9]
A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.

J Am Coll Cardiol. 2017-2-14

[10]
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.

J Am Coll Cardiol. 2016-12-27

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索